menu search

VRNA / Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript

Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q3 2023 Results Conference Call November 2, 2023 9:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hahn - CFO Dr. Kathy Rickard - Chief Medical Officer Chris Martin - SVP, Commercial Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Andreas Argyrides - Wedbush Securities Tom Shrader - BTIG Dipesh Patel - H.C. Wainwright Operator Welcome to Verona Pharma's Third Quarter 2023 Financial Results and Operating Highlights Conference Call. Read More
Posted: Nov 4 2023, 11:58
Author Name: Seeking Alpha
Views: 071861

VRNA News  

Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 4, 2023

Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript

Verona Pharma plc (NASDAQ:VRNA ) Q3 2023 Results Conference Call November 2, 2023 9:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hah more_horizontal

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

By GlobeNewsWire
October 19, 2023

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-st more_horizontal

Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround

By Zacks Investment Research
October 4, 2023

Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround

Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressur more_horizontal

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

By GlobeNewsWire
October 3, 2023

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine,  an investigational, novel, se more_horizontal

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

By GlobeNewsWire
September 6, 2023

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PD more_horizontal

Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon

By Seeking Alpha
September 4, 2023

Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon

Verona Pharma has submitted a New Drug Application (NDA) for ensifentrine, a potential treatment for COPD, to the FDA. The FDA has a 60-day window to more_horizontal

Verona Pharma: Financial Health And COPD Market Impact 2024

By Seeking Alpha
August 24, 2023

Verona Pharma: Financial Health And COPD Market Impact 2024

Verona Pharma is seeking FDA approval for its COPD treatment, ensifentrine, in 2024. The company has a strong financial position with substantial cash more_horizontal

Verona Pharma: Targeting The Large COPD Market

By Seeking Alpha
August 8, 2023

Verona Pharma: Targeting The Large COPD Market

Verona Pharma plc is a London-based biopharma company focused on developing respiratory disease treatments. The company recently submitted a NDA for i more_horizontal


Search within

Pages Search Results: